FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors


Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12015018263307/02/15 new patent  Immunoconjugates with an intracellularly-cleavable linkage
22015018388007/02/15 new patent  Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
32015017426906/25/15Immunoconjugates with an intracellularly-cleavable linkage
42015017427006/25/15Immunoconjugates with an intracellularly-cleavable linkage
52015016507506/18/15Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
62015016507606/18/15Anti-mucin antibodies for early detection and treatment of pancreatic cancer
72015016665906/18/15Humanized l243 antibodies
82015016666906/18/15Anti-cd74 immunoconjugates and methods of use
92015015096906/04/15Chimeric and humanized anti-histone antibodies
102015013276805/14/15Anti-pancreatic cancer antibodies
112015012538605/07/15Humanized anti-ceacam5 antibody and uses thereof
122015011127904/23/15Class i anti-cea antibodies and uses thereof
132015009445604/02/15Anthracycline-antibody conjugates for cancer therapy
142015008648203/26/15Dye conjugated peptides for fluorescent imaging
152015005743202/26/15Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
162015003868602/05/15Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
172015001851601/15/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
182014037717312/25/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
192014037717712/25/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
202014037728712/25/14Anti-trop-2 antibody-drug conjugates and uses thereof
212014036992712/18/14Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
222014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
232014028686109/25/14Rs7 antibodies
242014023420908/21/14Chimeric and humanized anti-histone antibodies
252014022717808/14/14Humanized anti-hla-dr antibodies
262014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
272014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
282014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
292014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
302014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
312014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
322014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
332014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
342014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
352014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
362014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
372014014092405/22/14Humanized l243 antibodies
382014012003505/01/14Rs7 antibodies
392014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
402014011286504/24/14Anti-cd19 antibodies
412014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
422014009925804/10/14Camptothecin-binding moiety conjugates
432014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
442014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
452014007962903/20/14Class i anti-cea antibodies and uses thereof
462014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
472014004463902/13/14Antibody therapy
482014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
492014003754302/06/14Anti-pancreatic cancer antibodies
502014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
512014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
522014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
532014001719701/16/14Anti-cd19 antibodies
542014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
552013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
562013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
572013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
582013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
592013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
602013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
612013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
622013017106407/04/13Anti-cd74 immunoconjugates and methods of use
632013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
642013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
652013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
662013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
672013015669106/20/13Antibody therapy
682013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
692013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
702013012191305/16/13Anti-cd19 antibodies
712013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
722013009503404/18/13Anti-cd74 immunoconjugates and methods
732013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
742013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
752013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
762013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
772013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
782013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
792013003986102/14/13Dye conjugated peptides for fluorescent imaging
802013003449202/07/13Class i anti-cea antibodies and uses thereof
812012032856412/27/12Camptothecin-binding moiety conjugates
822012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
832012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
842012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
852012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
862012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
872012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
882012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
892012018954207/26/12Anti-cd19 antibodies
902012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
912012018355007/19/12Therapeutic using a bispecific antibody
922012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
932012014137206/07/12Rs7 antibodies
942012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
952012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
962012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
972012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
982012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
992012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
1002012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1012012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
1022012003979702/16/12Antibody therapy
1032012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1042012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
1052011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1062011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1072011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1082011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
1092011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1102011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1112011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1122011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1132011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1142011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1152011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1162011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1172011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1182011022364509/15/11Multivalent carriers of bi-specific antibodies
1192011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1202011018908508/04/11Antibody therapy
1212011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1222011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1232011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1242011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1252011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1262011011710505/19/11Method of treating immune disease using b-cell antibodies
1272011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1282011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1292011007015503/24/11Anti-cd74 immunoconjugates and methods
1302011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1312011006465303/17/11Class i anti-cea antibodies and uses thereof
1322011005248903/03/11Anti-cd19 antibodies
1332010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1342010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1352010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1362010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1372010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1382010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1392010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1402010022117509/02/10Antibody therapy
1412010022117709/02/10Rs7 antibodies
1422010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1432010020296108/12/10D-amino acid peptides
1442010019626608/05/10Humanized anti-hla-dr antibodies
1452010019626708/05/10Humanized l243 antibodies
1462010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1472010018964107/29/10Novel strategies for improved cancer vaccines
1482010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1492010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1502010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1512010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1522010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1532010006813603/18/10Anti-cd19 antibodies
1542010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1552010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1562010001504601/21/10Camptothecin-binding moiety conjugates
1572010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1582010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1592010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1602009030458012/10/09Anti-pancreatic cancer antibodies
1612009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1622009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1632009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1642009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1652009025273110/08/09Multivalent carriers of bi-specific antibodies
1662009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1672009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1682009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1692009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1702009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1712009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1722009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1732009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1742009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1752009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1762009009259804/09/09Antibody therapy
1772010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1782010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE